EP0647133A4 - Compositions et procedes destines a ameliorer la liberation et l'acheminement de medicaments. - Google Patents

Compositions et procedes destines a ameliorer la liberation et l'acheminement de medicaments.

Info

Publication number
EP0647133A4
EP0647133A4 EP93915319A EP93915319A EP0647133A4 EP 0647133 A4 EP0647133 A4 EP 0647133A4 EP 93915319 A EP93915319 A EP 93915319A EP 93915319 A EP93915319 A EP 93915319A EP 0647133 A4 EP0647133 A4 EP 0647133A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
drug delivery
enhanced drug
enhanced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93915319A
Other languages
German (de)
English (en)
Other versions
EP0647133A1 (fr
Inventor
Ron L Hale
Amy Lu
Dennis Solas
Harold E Selick
Kevin R Oldenburg
Alejandro C Zaffaroni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affymax Technologies NV
Original Assignee
Affymax Technologies NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affymax Technologies NV filed Critical Affymax Technologies NV
Publication of EP0647133A1 publication Critical patent/EP0647133A1/fr
Publication of EP0647133A4 publication Critical patent/EP0647133A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP93915319A 1992-06-12 1993-06-11 Compositions et procedes destines a ameliorer la liberation et l'acheminement de medicaments. Withdrawn EP0647133A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US89821992A 1992-06-12 1992-06-12
US898219 1992-06-12
US946393A 1993-01-27 1993-01-27
US9463 1993-01-27
PCT/US1993/005631 WO1993025197A1 (fr) 1992-06-12 1993-06-11 Compositions et procedes destines a ameliorer la liberation et l'acheminement de medicaments

Publications (2)

Publication Number Publication Date
EP0647133A1 EP0647133A1 (fr) 1995-04-12
EP0647133A4 true EP0647133A4 (fr) 1997-10-29

Family

ID=26679515

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93915319A Withdrawn EP0647133A4 (fr) 1992-06-12 1993-06-11 Compositions et procedes destines a ameliorer la liberation et l'acheminement de medicaments.

Country Status (3)

Country Link
EP (1) EP0647133A4 (fr)
AU (1) AU4534593A (fr)
WO (1) WO1993025197A1 (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US6610841B1 (en) 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
ES2123133T3 (es) * 1993-03-10 1999-01-01 Magainin Pharma Derivados esteroidianos, composiciones farmaceuticas que contienen estos derivados esteroidianos y utilizacion de estos ultimos como antibioticos o desinfectantes.
US5505715A (en) * 1994-02-25 1996-04-09 Bristol-Myers Squibb Company Iontophoretic transdermal delivery of deoxyspergualin compounds
US6468981B1 (en) * 1994-07-29 2002-10-22 Emory University Compositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors
US5840740A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds and a method of treating infection using the aminosterol compounds
US5856535A (en) * 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
FR2727117A1 (fr) * 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
ATE241346T1 (de) † 1995-03-02 2003-06-15 Scherer Technologies Inc R P Arzneimittel enthaltend monoaminooxidase-b-hemmer
US8071737B2 (en) 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
US5747453A (en) 1995-06-06 1998-05-05 Alza Corporation Method for increasing the electrotransport flux of polypeptides
IT1285405B1 (it) * 1995-06-06 1998-06-03 Alza Corp Modificazione di farmaci polipeptidici per accrescere il flusso per elettrotrasporto.
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US5847172A (en) * 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5795885A (en) * 1995-06-07 1998-08-18 Magainin Pharmaceuticals Inc. Method of inhibiting profileration of cells by administering an aminosterol compound
US5840936A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US6143738A (en) * 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
US5874597A (en) * 1995-06-07 1999-02-23 Magainin Pharmaceuticals, Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5763430A (en) * 1995-06-07 1998-06-09 Magainin Pharmaceuticals Inc. Method of treating a viral infection by administering a steroid compound
US5994336A (en) * 1995-06-07 1999-11-30 Magainin Pharmaceuticals Inc. Method of inhibiting proliferation of cells by administering an aminosterol compound
IT1283955B1 (it) * 1996-03-20 1998-05-07 Sigma Tau Ind Farmaceuti Bis alcanoil esteri della carnitina ad attivita' antibatterica, antimicotica ed antiprotozoaria.
US6596712B2 (en) 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
CA2252584C (fr) * 1996-04-26 2008-06-10 Magainin Pharmaceuticals Inc. Traitement des carcinomes par la squalamine en association avec d'autres agents anticancereux
US6333189B1 (en) 1996-06-06 2001-12-25 Alza Corporation Method of making an electrotransport device
US6262283B1 (en) 1996-12-06 2001-07-17 Magainin Pharmaceuticals Inc. Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds
IT1299266B1 (it) * 1998-05-15 2000-02-29 Sigma Tau Ind Farmaceuti Inibitori reversibili della carnitina palmitoil trasferasi
CA2406847C (fr) 2000-04-12 2009-11-17 Genaera Corporation Oxydation stereoselective de systemes a cycles fusionnes pour la preparation d'aminosterols
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
ES2296956T5 (es) 2001-06-11 2011-07-12 Xenoport, Inc. Profármacos de análogos de gaba, composiciones y sus usos.
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
GB0116047D0 (en) * 2001-06-29 2001-08-22 Implyx Ltd Peptide motif for therapy
DE10303669A1 (de) * 2003-01-28 2004-07-29 Hans-Knöll-Institut für Naturstoff-Forschung e.V. Tetraalkylammoniumsalze vom Kohlensäureestertyp, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US8795725B2 (en) 2004-11-04 2014-08-05 Xenoport, Inc. GABA analog prodrug sustained release oral dosage forms
ATE426610T1 (de) * 2005-02-04 2009-04-15 Us Gov Health & Human Serv Nandrolon-17ss-carbonate
US20090221703A1 (en) 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
US20090238763A1 (en) 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
TW200820963A (en) 2006-07-28 2008-05-16 Xenoport Inc Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use
CN101522692A (zh) * 2006-10-11 2009-09-02 于崇曦 具有快速皮肤穿透速度的带正电荷的水溶性的昔康及其相关化合物的前药
AU2007345952C1 (en) * 2007-01-31 2017-06-08 Chongxi Yu Positively charged water-soluble prodrugs of 1H-imidazo[4, 5-c]quinolin-4-amines and related compounds with very high skin penetration rates
JP5276020B2 (ja) * 2007-02-13 2013-08-28 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ カチオン性エストラジオール誘導体、その合成方法、及び医薬組成物
KR20180049144A (ko) 2007-06-04 2018-05-10 테크필즈 인크 매우 높은 피부 및 막 침투율을 가지는 비스테로이드성 소염제(ｎｓａｉａ) 약물전구체 및 이들의 새로운 의약적 용도
EP2219587A4 (fr) * 2007-11-14 2012-11-21 Univ California Lipides amphiphiles modifiés par un stérol
JP2012511027A (ja) 2008-12-04 2012-05-17 チョンシー ユー 高透過性組成物およびその用途
AU2010266040B2 (en) 2009-06-25 2015-01-15 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
PT2445502T (pt) 2009-06-25 2017-09-22 Alkermes Pharma Ireland Ltd Compostos heterocíclicos para o tratamento de distúrbios neurológicos e psicológicos
CN103980338B (zh) 2010-01-15 2017-04-26 苏州润新生物科技有限公司 蟾蜍灵衍生物、其药物组合物及用途
CA2802733C (fr) 2010-06-24 2017-11-21 Alkermes Pharma Ireland Limited Promedicaments de composes nh-acides : derives esters, carbonates, carbamates et phosphonates
WO2012027957A1 (fr) 2010-08-28 2012-03-08 Suzhou Neupharma Co., Ltd. Dérivés de bufaline, compositions pharmaceutiques et utilisation de ceux-ci
EP2670763B1 (fr) * 2011-02-02 2018-08-01 Suzhou Neupharma Co., Ltd Certaines entités chimiques, compositions et procédés
RU2627469C2 (ru) 2011-03-18 2017-08-08 Алкермес Фарма Айэленд Лимитед Фармацевтические композиции, содержащие водонерастворимое антипсихотическое средство и сложные эфиры сорбита
CN103607888A (zh) * 2011-04-08 2014-02-26 斯法尔制药私人有限公司 取代的甲基甲酰基试剂以及使用所述试剂改进化合物的物理化学性质和/或药代动力学性质的方法
EP2790734B1 (fr) 2011-12-15 2019-02-20 Alkermes Pharma Ireland Limited Promédicaments de composés amine secondaires
US10004807B2 (en) 2012-03-19 2018-06-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
NZ630428A (en) 2012-03-19 2017-02-24 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising benzyl alcohol
AU2013235523B9 (en) 2012-03-19 2018-01-04 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
WO2013165924A1 (fr) 2012-04-29 2013-11-07 Neupharma, Inc. Certaines entités chimiques, compositions et procédés
NZ748572A (en) 2012-09-19 2020-07-31 Alkermes Pharma Ireland Ltd Pharmaceutical compositions having improved storage stability
CN103896791B (zh) * 2012-12-25 2016-12-28 广东隆赋药业股份有限公司 乙酰左卡尼汀盐酸盐的制备方法
GB201308363D0 (en) 2013-05-09 2013-06-19 Bagshawe Kenneth D Tumour therapy
AU2015231278B2 (en) 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
CN104151452B (zh) * 2014-07-16 2017-02-01 西北大学 聚n‑(2‑羟丙基)甲基丙烯酰胺‑氯尼达明大分子前药及其制备方法
AU2019230014A1 (en) 2018-03-05 2020-09-17 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
US12065404B2 (en) 2022-03-18 2024-08-20 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
CN115851076B (zh) * 2022-12-21 2023-10-31 湖北航天化学技术研究所 一种石墨烯含锌防锈漆及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3023206A1 (de) * 1979-11-02 1982-01-14 Efeka Friedrich & Kaufmann GmbH & Co KG, 3000 Hannover Indometacin-ester, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4386026A (en) * 1981-04-20 1983-05-31 Merck & Co., Inc. Cell-specific glycopeptide ligands
EP0279887A2 (fr) * 1987-01-15 1988-08-31 Alfred Stracher Agents pharmaceutiques dirigés par la carnitine et leur utilisation pour la fabrication d'un médicament pour le traitement d'une maladie musculaire
EP0289262A2 (fr) * 1987-04-27 1988-11-02 Syntex Pharmaceuticals International Limited Alkylesters d'ammonium quaternaire-oméga et thioesters de médicaments antiinflammatoires acides non stéroiques
WO1991009831A1 (fr) * 1989-12-26 1991-07-11 Nova Pharmaceutical Corporation Anhydrides sous forme de promedicaments d'aspirine, d'indomethacine et d'ibuprofene, leur preparation, leurs compositions, et leur mode anti-inflammatoire d'emploi
US5042975A (en) * 1986-07-25 1991-08-27 Rutgers, The State University Of New Jersey Iontotherapeutic device and process and iontotherapeutic unit dose

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US5085749A (en) * 1989-03-14 1992-02-04 Massachusetts Institute Of Technology Dynamically controlled membrane

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3023206A1 (de) * 1979-11-02 1982-01-14 Efeka Friedrich & Kaufmann GmbH & Co KG, 3000 Hannover Indometacin-ester, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4386026A (en) * 1981-04-20 1983-05-31 Merck & Co., Inc. Cell-specific glycopeptide ligands
US5042975A (en) * 1986-07-25 1991-08-27 Rutgers, The State University Of New Jersey Iontotherapeutic device and process and iontotherapeutic unit dose
EP0279887A2 (fr) * 1987-01-15 1988-08-31 Alfred Stracher Agents pharmaceutiques dirigés par la carnitine et leur utilisation pour la fabrication d'un médicament pour le traitement d'une maladie musculaire
EP0289262A2 (fr) * 1987-04-27 1988-11-02 Syntex Pharmaceuticals International Limited Alkylesters d'ammonium quaternaire-oméga et thioesters de médicaments antiinflammatoires acides non stéroiques
WO1991009831A1 (fr) * 1989-12-26 1991-07-11 Nova Pharmaceutical Corporation Anhydrides sous forme de promedicaments d'aspirine, d'indomethacine et d'ibuprofene, leur preparation, leurs compositions, et leur mode anti-inflammatoire d'emploi

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9325197A1 *

Also Published As

Publication number Publication date
AU4534593A (en) 1994-01-04
EP0647133A1 (fr) 1995-04-12
WO1993025197A1 (fr) 1993-12-23

Similar Documents

Publication Publication Date Title
EP0647133A4 (fr) Compositions et procedes destines a ameliorer la liberation et l'acheminement de medicaments.
ZA942804B (en) Oral drug delivery compositions and methods
EP0658111A4 (fr) Procedes destines a faciliter l'apport de medicaments a l'aide de saponines modifiees.
IL109661A0 (en) Drug delivery device
EP0662851A4 (fr) Systeme d'administration de medicaments.
GB2271059B (en) Pharmaceutical compositions comprising aconitane derivatives and tetrahydroprotoberberine derivatives.
IL110588A0 (en) Bioadhesive emulsion preparations for enhanced drug delivery
EP0491812A4 (en) Drug delivery compositions
EP0676963A4 (fr) Compositions pharmaceutiques a base d'acide hyaluronique et d'uree, et leurs utilisations.
EP0683668A4 (fr) Compositions et procedes d'administration transdermique de medicaments.
GB2272375B (en) Pharmaceutical composition
AU1432292A (en) Drug delivery composition and method of using the same
GB9325330D0 (en) Fluorocyclodextrin drug delivery system
EP0600754A3 (fr) Transfuseur pharmaceutique à débit continu.
GB9404293D0 (en) Drug delivery system
IL107122A0 (en) 3-substituted 2-oxindole-1-carboxamide pharmaceutical compositions
EP0636363A3 (fr) Système pour la délivrance d'un médicament.
GB2292887B (en) Drug delivery system
GB9223363D0 (en) Drug etc.delivery
ZA931775B (en) Drug delivery devices.
GB9303117D0 (en) Drug delivery system
GB9324682D0 (en) Drug delivery system
GB9307904D0 (en) Drug delivery system
ZA93286B (en) Pharmaceutical compositions.
IL102718A0 (en) Method and pharmaceutical compositions for drug targeting

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): CH DE FR GB IT LI NL

RHK1 Main classification (correction)

Ipc: A61K 47/48

A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): CH DE FR GB IT LI NL

17Q First examination report despatched

Effective date: 19980120

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980603